Squarepoint’s Alaunos Therapeutics TCRT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-2,975
Closed -$31.6K 4600
2023
Q4
$31.6K Buy
+2,975
New +$35.8K ﹤0.01% 3889
2023
Q2
Sell
-711
Closed -$67.2K 4007
2023
Q1
$67.2K Buy
711
+634
+823% +$60.4K ﹤0.01% 3026
2022
Q4
$7.47K Buy
+77
New +$11.2K ﹤0.01% 3123
2022
Q1
Sell
-879
Closed -$144K 3504
2021
Q4
$144K Sell
879
-486
-36% -$107K ﹤0.01% 2828
2021
Q3
$373K Sell
1,365
-53
-4% -$16.2K ﹤0.01% 2139
2021
Q2
$562K Buy
1,418
+178
+14% +$83.1K ﹤0.01% 2040
2021
Q1
$669K Buy
1,240
+1,146
+1,219% +$713K ﹤0.01% 1811
2020
Q4
$36K Sell
94
-281
-75% -$112K ﹤0.01% 2823
2020
Q3
$142K Sell
375
-391
-51% -$173K ﹤0.01% 2210
2020
Q2
$377K Buy
+766
New +$342K 0.01% 1466
2020
Q1
Sell
-885
Closed -$626K 2495
2019
Q4
$626K Buy
885
+724
+450% +$498K ﹤0.01% 1629
2019
Q3
$103K Buy
+161
New +$128K ﹤0.01% 2186
2019
Q1
Sell
-220
Closed -$62K 2432
2018
Q4
$62K Buy
+220
New +$87K ﹤0.01% 1836
2018
Q3
Sell
-291
Closed -$132K 2217
2018
Q2
$132K Buy
291
+127
+77% +$80.5K ﹤0.01% 1615
2018
Q1
$97K Buy
+164
New +$102K ﹤0.01% 1575
2017
Q3
Sell
-385
Closed -$359K 1871
2017
Q2
$359K Buy
+385
New +$377K 0.01% 1072
2017
Q1
Sell
-408
Closed -$327K 1891
2016
Q4
$327K Buy
+408
New +$368K 0.01% 1102
2016
Q3
Sell
-125
Closed -$103K 1250
2016
Q2
$103K Sell
125
-368
-75% -$401K 0.01% 975
2016
Q1
$549K Sell
493
-14
-3% -$14.3K 0.04% 579
2015
Q4
$632K Buy
+507
New +$839K 0.07% 426
2015
Q2
Sell
-207
Closed -$334K 599
2015
Q1
$334K Buy
+207
New +$307K 0.12% 269

Other funds holding TCRT

Squarepoint's TCRT Position: Q1 2024 in Review

Squarepoint sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 2,975 shares — an estimated $31.6K sold.

Squarepoint first reported a position in TCRT in Q1 2015 and held it in 21 quarters. The position peaked at $669K in Q1 2021. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

  • Squarepoint reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Squarepoint sold 2,975 Alaunos Therapeutics shares in Q1 2024, an estimated $31.6K.
  • Squarepoint first reported a position in Alaunos Therapeutics in Q1 2015 and held it in 21 quarters.
  • Squarepoint's Alaunos Therapeutics position peaked at $669K in Q1 2021.
  • 45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Squarepoint's 13F filing for Q1 2024, filed 15 May 2024.